Health Catalyst (HCAT) to Release Quarterly Earnings on Monday

Health Catalyst (NASDAQ:HCAT) is anticipated to issue its Q3 2025 results after the market closes on Monday, November 10th. Analysts expect Health Catalyst to post earnings of $0.05 per share and revenue of $75.05 million for the quarter. Interested persons can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Monday, November 10, 2025 at 5:00 PM ET.

Health Catalyst Stock Down 1.5%

HCAT stock opened at $3.23 on Monday. Health Catalyst has a one year low of $2.52 and a one year high of $9.24. The firm has a market cap of $227.30 million, a PE ratio of -2.14 and a beta of 1.64. The firm’s 50 day moving average price is $3.11 and its 200-day moving average price is $3.55. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.83 and a current ratio of 1.83.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Summit Redstone set a $5.00 target price on Health Catalyst in a research note on Friday, August 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Health Catalyst in a research note on Wednesday, October 8th. Canaccord Genuity Group cut their target price on Health Catalyst from $9.00 to $5.00 and set a “buy” rating for the company in a research note on Friday, August 29th. Cantor Fitzgerald reissued a “neutral” rating and set a $4.00 target price on shares of Health Catalyst in a research note on Tuesday, October 7th. Finally, Piper Sandler cut Health Catalyst from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $8.00 to $4.00 in a research note on Wednesday, August 27th. Three analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $4.55.

Hedge Funds Weigh In On Health Catalyst

Large investors have recently made changes to their positions in the stock. Focus Partners Wealth acquired a new position in shares of Health Catalyst in the 1st quarter worth approximately $46,000. Cresset Asset Management LLC acquired a new stake in Health Catalyst during the 2nd quarter worth approximately $39,000. The Manufacturers Life Insurance Company lifted its holdings in Health Catalyst by 19.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,491 shares of the company’s stock worth $100,000 after buying an additional 4,341 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Health Catalyst by 7.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 36,047 shares of the company’s stock worth $163,000 after buying an additional 2,624 shares in the last quarter. Finally, Jane Street Group LLC acquired a new stake in Health Catalyst during the 2nd quarter worth approximately $173,000. 85.00% of the stock is currently owned by institutional investors and hedge funds.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.